SCHEMBL10072892

SCHEMBL10072892

O=S(=O)(c1n[nH]c2ncccc12)N1CCCCC1c1cccnc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.62
CYP2C19 P33261 1/20 0.62
ALDH1A1 P00352 5/20 0.59
USP2 O75604 1/20 0.59
POLB P06746 3/20 0.56
ADRB2 P07550 3/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.52
MAPT P10636 5/20 0.50
MAPK1 P28482 2/20 0.50
HTT P42858 2/20 0.50
LMNA P02545 2/20 0.50
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
NUDT1 P36639 1/20 0.47
THRB P10828 1/20 0.47
KDM4E B2RXH2 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA7 P36544 1/20 0.47
CHRNA4 P43681 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073467 0.97 CYP3A4 (0.57) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL10072922 0.82 ALOX15 (0.54) ALDH1A1KMT2AHTTLMNASMN1; SMN2
SCHEMBL10073640 0.79 ALOX15 (0.49) ALDH1A1KMT2AHTTLMNASMN1; SMN2
SCHEMBL10072913 0.77 COMT (0.42)
SCHEMBL10072897 0.76 COMT (0.49) CYP3A4CYP2C19ALDH1A1USP2TSHR
SCHEMBL10072901 0.76 PIM1 (0.44) ALDH1A1USP2POLBTSHRKMT2A
SCHEMBL1645112 0.75 CYP3A4 (0.70) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL10072905 0.75 KDM4E (0.50) CYP3A4CYP2C19ALDH1A1USP2TSHR
SCHEMBL5307006 0.74 CYP3A4 (0.80) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL396700 0.74 ALDH1A1 (1.00) CYP3A4CYP2C19ALDH1A1USP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445681-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-21 US disclosed
EP-2514751-A1 Azaindazoles useful as inhibitor of kinases Vertex Pharmaceuticals, Inc. (US) 2012-10-24 EP disclosed
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-28 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases PRKDC, MAP3K20, PRKACA CYP3A4 2515/4885CYP2C19 2166/4885ALDH1A1 3237/4885
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES PRKDC, MAP3K20, PRKACA CYP3A4 2515/4885CYP2C19 2166/4885ALDH1A1 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.